Inflammation and immune suppression fuel aggressive SCLC behavior and spread
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year…
Study finds a new protein target against KRAS-driven non-small cell lung cancer
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.…
How COVID mRNA vaccines may make cancer treatments more effective
A new study reveals that SARS-CoV-2 mRNA vaccines can amplify immune checkpoint therapy in lung and skin cancers…
Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest…